The development of genetically engineered T-cells constitutes a powerful new class of therapeutic agents that offers a new hope for cancer patients.
CAR T-cells in acute leukemia and diffuse large B-cell lymphoma were recently approved by the FDA and EMA and more than one hundred clinical trials are ongoing. This is definitely an emerging therapeutic breakthrough.
The aim of the Cell Therapy Innovation 360° (CTI 360°) congress is to become a reference in cell-therapy perspectives and issues in Onco-hematology issues. CTI 360° will bring together all the key French and European players in the field on May 21 and 22, 2019, in Lyon, France. [...]